

CROHN'S/ UC REFERRAL FORM

Fax: 800-269-5493 Phone: 888-292-0744

A Carelon Compo	any		-									bi	oplus	rx.com		
PATIENT INFORMATI	ON															
Patient's Name:	SSN	SSN:					DOB:									
Address:				City	City:				5	State:		Zip:				
Home Phone: Cell:				Heig	Height:			Weight:				Gender:	Male	Female		
Email	Diagnosis Code:															
INSURANCE INFORM	ATION (or at	ltach cop	oy of the cards)													
Primary Insurance:			Policy Holder:		Relationship:			Poli			olicy #:			Group #:		
Secondary Insurance:			Policy Holder:		Relationship:			Poli			Policy #:			Group #:		
PRESCRIPTION INFO	RMATION (fo	r IV med	ication attach a copy of	the p	rescr	iption)										
AMJEVITA™ (adalimumab-e SureClick 40 mg/0.8 mL □ nduction: 160 mg SubQ Day □ x 40 mg SubQ in one day □ 2 x 40 mg SubQ Day 15 Qty: 6 Maintenance:	SIMPONI® (golimumab) ☐ Prefilled Syringe ☐ Autoinjector ☐ Induction: 200 mg (2 x 100 mg) SubQ at week 0 Qty: 2 syringes Refills: 0 SKYRIZI™ (risankizumab-rzaa)															
□ 40,mg SubQ every other worty: □□ CIMZIA®(certolizumab pegol □ Prefilled Syringe □ Lyc □ Induction: 400 mg (2 x 200 Ωty: 28 day supply Maintenance: □ 2 x 200 mg SubQ every 4 w □ 2 x 200 mg SubQ every 2 w	□ OBI □ VIAL □ Induction: 600 mg intravenously weeks 0, 4, 8 Qty: 1 Refills: 0 □ Maintenance: □ 180 mg SubQ week12, then every 8 weeks □ 360 mg SubQ week12, then every 8 weeks Qty:1 STELARA® (ustekinumab)															
□ 200 mg SūbQ every 2 week Qty: 28 day supply DUPIXENT® (dupilumab)	□ IV Induction: □ 260 mg (pt weight: ≤ 55 kg) □ 390 mg (pt weight: 56-85 kg) □ 520 mg (pt weight: >85 kg) Qty: □ Refills: 0 □ Maintenance: Starting 8 weeks after IV induction dose, 90 mg SubQ every 8 weeks Qty: 1															
□ Prefilled Syringe □ Pen□ Inject 300 mg SubQ every□ Qty: 4 for 28 days	SOLESTA® (dextranomer and sodium hyaluronate) 1 ml Prefilled Syringe 4 submucosal injections Qty: 4 Refills:															
Entocort® (budesonide) B mg capsules □ 9 mg PO daily attv: 90 Refills:					UCERIS® (budesonide) 9 mg Extended-Release Tablet 9 mg PO daily Qty: 30 Refills:											
Qty: 90 HUMIRA® (adalimumab) □ Pen □ Pre □ Citrate Free (CF) □ Ori nduction: □ 160 mg SubQ day 1, 80 mg	XELJANZ® (tofacitinib) Induction: 10 mg PO twice daily for 8-16 week Qty: Refills: Qty: 60 Refills:															
□ 80 mg SubQ day 1, 80 mg S Qty: 1 pack □ Maintenance: 10 mg SubQ every other week Qty: 28 day supply ** If dosage form	XIFAXAN® (rifaximin) ☐ 200 mg tablet ☐ 550 mg tablet ☐ 550 mg tablet ☐ 550 mg PO three times per day for 14 days ☐ 200 mg PO three times per day for 16 days ☐ mg POtimes per day fordays ☐ days ☐ times per day fordays ☐ Refills: ☐															
RINVOQ® (upadacitinib) exte 15 mg	ZEPOSIA® (ozanimod) ☐ 7-day titration: days 1-4: Give 0.23 mg PO once daily. days 5 to 7: Give 0.46 mg PO daily Qty: 1 Refills: None ☐ Maintenance Dosing: Starting day 8, 0.92 mg PO once daily Qty: 30 Refills: Refills:															
MMUNOSUPPRESSIV AVSOLA® □ E Initial Dose:m Other:m		CADE [®] □ RENFLEXIS [®] mg/kg every 8 weeks efills:														
□ OTHER STI	RENGTH:	SIG/E	DIRECTIONS:						R	REFILLS	S :	QUANT	TTY:			
s required by your state, Pres		ispense as w	ritten" or handwrite "Brand Medically	Necessa	ary"	☐ Dispense	e as written									
PHYSICIAN INFORMA				Inject	ion T	raining:	Of	fice to	Inst	ruct	SP	to Arrar	ige Tea	aching		
Prescriber Name:			Phone:				Fax:									
Office Contact:						Email:										
Address:	Ship To: Patient MD Office															
NPI #:	Tax ID#:															
Prescription Signature:						Date:										